Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Description

The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.

Conditions

Squamous Cell Carcinoma, Nonmelanoma Skin Cancer, Cutaneous Squamous Cell Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Condition
Squamous Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Indianapolis

Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States, 46202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients ≥ 18 years old at the time of informed consent
  • * Ability to provide written informed consent and HIPAA authorization
  • * Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging
  • * Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)
  • * Able to undergo general anesthesia for sentinel lymph node biopsy
  • * Able to undergo CT scan with contrast or MRI with contrast
  • * Undergo surgical resection (Moh's or micrographic resection or standard excision with sentinel lymph node biopsy) within 8 weeks of imaging
  • * Clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases
  • * Known biopsy proven synchronous primary cutaneous squamous cell carcinoma
  • * Pregnant patients
  • * Patients unable to undergo general anesthesia
  • * Patient unable to receive contrasted imaging studies
  • * Patient unable to receive and/or allergic to 99m-Technetium sulfur colloid

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Indiana University,

Jessica Yesensky, MD, PRINCIPAL_INVESTIGATOR, Indiana University

Study Record Dates

2026-09